Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.36 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19604526 | 1.00 | BTK (0.45) | BTKANPEPTSHREPHX2SLC6A1 | |
| SCHEMBL14447179 | 1.00 | BTK (0.45) | BTKANPEPTSHREPHX2SLC6A1 | |
| SCHEMBL824158 | 0.87 | ACE (0.39) | BTKANPEPTSHRLMNAACE | |
| SCHEMBL14436548 | 0.87 | ACE (0.39) | BTKANPEPTSHRLMNAACE | |
| SCHEMBL25544633 | 0.87 | ACE (0.39) | BTKANPEPTSHRLMNAACE | |
| SCHEMBL25544782 | 0.87 | ACE (0.39) | BTKANPEPTSHRLMNAACE | |
| SCHEMBL9504406 | 0.84 | ANPEP (0.46) | BTKANPEPTSHREPHX2SLC6A1 | |
| SCHEMBL9504417 | 0.84 | ANPEP (0.46) | BTKANPEPTSHREPHX2SLC6A1 | |
| SCHEMBL12926820 | 0.84 | BTK (0.42) | BTKANPEPTSHREPHX2SLC6A1 | |
| SCHEMBL9505565 | 0.84 | ANPEP (0.46) | BTKANPEPTSHREPHX2SLC6A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016795-A1 | BROMODOMAIN INHIBITORS FOR ANDROGEN RECEPTOR-DRIVEN CANCERS | FORMA THERAPEUTICS INC (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2023235753-A2 | ALDH2 INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-11801243-B2 | Bromodomain inhibitors for androgen receptor-driven cancers | FORMA THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-RE49352-E1 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220162207-A1 | INHIBITING CREB BINDING PROTEIN (CBP) | FORMA THERAPEUTICS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-11254674-B2 | Inhibiting CREB binding protein (CBP) | FORMA THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210244711-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-12 | — | — | US | disclosed |
| US-10870648-B2 | Inhibiting CREB binding protein (CBP) | FORMA THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200299295-A1 | INHIBITING CREB BINDING PROTEIN (CBP) | FORMA THERAPEUTICS, INC. | 2020-09-24 | — | — | US | disclosed |
| US-9062028-B2 | Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-20 | — | — | US | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8143287-B2 | Thrombopoietin mimetics | STATEGICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100323965-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-7786159-B2 | Thrombopoietin mimetics | STATEGICS, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080139621-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008070583-A2 | THROMBOPOIETIN MIMETICS | STATEGICS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162207-A1 | INHIBITING CREB BINDING PROTEIN (CBP) | CREBBP, EP300, CREB1 | BTK 2531/4885ANPEP 3980/4885TSHR 2892/4885 |
| US-20210244711-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | BTK 1167/4885ANPEP 1644/4885TSHR 554/4885 |
| US-11254674-B2 | Inhibiting CREB binding protein (CBP) | CREBBP, EP300, CREB1 | BTK 2531/4885ANPEP 3980/4885TSHR 2892/4885 |
| US-20240016795-A1 | BROMODOMAIN INHIBITORS FOR ANDROGEN RECEPTOR-DRIVEN CANCERS | BRDT, AR, BRD4 | BTK 1215/4885ANPEP 1869/4885TSHR 1438/4885 |
| US-10870648-B2 | Inhibiting CREB binding protein (CBP) | CREBBP, EP300, CREB1 | BTK 2531/4885ANPEP 3980/4885TSHR 2892/4885 |
| US-20080139621-A1 | Thrombopoietin Mimetics | MPL, THPO, TEK | BTK 697/4885ANPEP 1001/4885TSHR 245/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | BTK 1662/4885ANPEP 1189/4885TSHR 2355/4885 |
| US-20100323965-A1 | Thrombopoietin Mimetics | MPL, THPO, TEK | BTK 697/4885ANPEP 1001/4885TSHR 245/4885 |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | GRK5, GPBAR1, GPR55 | BTK 2259/4885ANPEP 2948/4885TSHR 36/4885 |
| US-20200299295-A1 | INHIBITING CREB BINDING PROTEIN (CBP) | CREBBP, EP300, CREB1 | BTK 2531/4885ANPEP 3980/4885TSHR 2892/4885 |
| US-11801243-B2 | Bromodomain inhibitors for androgen receptor-driven cancers | BRDT, AR, BRD4 | BTK 1215/4885ANPEP 1869/4885TSHR 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.